| Literature DB >> 28507570 |
Janusz Siebert1, Łukasz Lewicki1, Jolanta Myśliwska2, Monika Młotkowska3, Jan Rogowski4.
Abstract
INTRODUCTION: Atrial fibrillation (AF) is a frequently encountered complication after coronary artery bypass grafting (CABG), but its underlying mechanisms are still unclear. The natriuretic peptides have been reported as markers for predicting the occurrence of postoperative AF. This study evaluates whether the ScaI ANP gene polymorphisms predict the occurrence of postoperative AF.Entities:
Keywords: ScaI ANP; atrial fibrillation; coronary artery bypass grafting; coronary artery disease; gene polymorphisms
Year: 2016 PMID: 28507570 PMCID: PMC5420619 DOI: 10.5114/aoms.2016.58270
Source DB: PubMed Journal: Arch Med Sci ISSN: 1734-1922 Impact factor: 3.318
Figure 1Genotyping by polyacrylamide gel electrophoresis of PCR–RFLP. A fragment of the ANP gene was amplified and products were digested with ScaI restriction enzyme, subsequently run on 12% polyacrylamide gel using 1% solution ethidium bromide to visualize the fragments
1 – Marker, 2 – ANP amplified product, 3 – the homozygous A1 allele appeared as 213 and 21-bp bands, 4 – the homozygous A2 allele appeared as bands of 117, 96 and 21 bp, 5 – the heterozygotes A1A2 exhibited all bands (213, 117, 96 and 21 bp).
ScaI ANP genotype frequency in 203 patients with ischaemic heart disease admitted for CABG
| ScaI ANP genotype | Number of patients (%) |
|---|---|
| A2A2 | 72 (35.5) |
| A1A2 | 121 (59.6) |
| A1A1 | 10 (4.9) |
CABG – coronary artery bypass grafting, ANP – atrial natriuretic peptide.
Clinical profile of 203 patients with ischaemic heart disease admitted for CABG and OPCABG according to ScaI ANP genotype. The analysis was made using the ANOVA test for continuous variables and χ2 test for categorical data
| Parameter | ScaI ANP genotype | |||
|---|---|---|---|---|
| A1A2 | A2A2 | A1A1 | ||
| Number of patients | 121 | 72 | 10 | |
| Age [years] | 62 ±9 | 64 ±8.9 | 63 ±7.19 | 0.7 |
| BMI | 27.9 ±4.1 | 25.7 ±3.9 | 28 ±2.9 | 0.5 |
| EuroSCORE | 3 (0; 9) | 3 (0; 10) | 4 (0; 6) | 0.6 |
| Duration of angina [years] | 8 ±7.5 | 8.8 ±7.4 | 10.9 ±9.7 | 0.004 (0.4) |
| NYHA | 1 ±0.73 | 1 ±0.76 | 1 ±0.69 | 0.8 |
| Total cholesterol [mg%] | 225.9 ±51.2 | 214 ±48 | 216 ±51 | 0.9 |
| LDL cholesterol [mg%] | 140.9 ±43.3 | 132 ±41 | 144 ±57.8 | 0.5 |
| HDL cholesterol [mg%] | 43.2 ±12.5 | 42 ±12 | 45 ±13 | 0.9 |
| Triglycerides [mg%] | 185.7 ±138.4 | 150.7 ±66.4 | 136 ±56 | 0.04 (0.1) |
| Creatinine [mg%] | 1.14 ±0.2 | 1.1 ±0.2 | 1.19 ±0.2 | 0.7 |
| EF | 53.6 ±10.2 | 52.8 ±11.3 | 47.5 ±9.5 | 0.9 |
| LA | 4 ±0.5 | 4 ±0.5 | 4.15 ±0.4 | 0.6 |
| LVESd | 3.5 ±0.8 | 3.6 ±0.7 | 4.1 ±1.2 | 0.3 |
| LVEDd | 5.2 ±0.8 | 5.2 ±0.6 | 5.6 ±0.8 | 0.9 |
| Male/female | 87/34 | 55/17 | 10/0 | 0.49 |
| Myocardial infarction history | 81 | 47 | 8 | 0.81 |
| Diabetes | 32 | 16 | 1 | 0.49 |
| Hypertension | 82 | 48 | 4 | 0.9 |
| Paroxysmal atrial fibrillation | 8 | 3 | 0 | 0.7 |
Values are expressed as median and range and were compared using the Kruskal-Wallis test,
p < 0.05. CABG – coronary artery bypass grafting, OPCABG – off-pump coronary artery bypass grafting, LA – left atrial diameter, LVESd – left ventricle systolic diameter, LVEDd – left ventricle end-diastolic diameter, ANP – atrial natriuretic peptide, BMI – body mass index, EF – ejection fraction.
Figure 2Incidence of atrial fibrillation after 203 CABG procedures
AF – atrial fibrillation, SR – sinus rhythm, CABG – coronary artery bypass grafting.
Relationship between ScaI ANP gene variants and the incidence of “new-onset” AF in 192 patients (after excluding patients with a history of paroxysmal AF before the operation). The analysis was made using a logistic regression model
| OR for “new-onset” atrial fibrillation A1A2 vs. A2A2 and A1A1 | OR = 0.65 (0.12–3.34) | |
| OR for “new-onset” atrial fibrillation A2A2 vs. non A2A2 | OR = 1.35 (0.59–3.07) | |
| OR for “new-onset” atrial fibrillation A1A1 vs. non A1A1 | OR = 1.8 (0.34–9.5) |
AF – atrial fibrillation, ANP – atrial natriuretic peptide.
Intra- and postoperative data in 203 CABG patients according the ScaI ANP genotype. The analysis was made using the ANOVA test for continuous variables and χ2 test for categorical data
| Parameter | ScaI ANP genotype | |||
|---|---|---|---|---|
| A1A2 | A2A2 | A1A1 | ||
| Number of patients | 121 | 72 | 10 | |
| Neuro-mental complications | 5 (4.1%) | 3 (4.1%) | 0 | 0.7 |
| Excessive bleeding | 7 (5.8%) | 2 (2.7%) | 0 | 0.4 |
| Peri-operative death | 2 (1.6%) | 2 (2.7%) | 0 | 0.9 |
| CABG/OPCABG | 59/62 | 29/43 | 7/3 | 0.2 |
| 1st day drainage [ml] | 562 ±300.5 | 554 ±258 | 586.25 ±269.2 | 0.8 |
| CPK-MB | 33.2 ±86.7 | 21 ±35.3 | 15.6 ±16.9 | 0.7 |
| CPB time [min] | 90.47 ±31.5 | 92.11 ±35.4 | 71.5 ±17.7 | 0.4 |
| Duration of aortic cross clamp [min] | 47.5 ±18.6 | 50 ±24 | 39.8 ±11.3 | 0.9 |
| Number of distal anastomoses | 2.63 ±0.9 | 2.69 ±0.9 | 3.1 ±0.9 | 0.2 |
CABG – coronary artery bypass grafting, OPCABG – off-pump coronary artery bypass grafting, ANP – atrial natriuretic peptide, CPB – cardiopulmonary bypass.